Nicholas J. Calamari, CAO and Senior Counsel, has demonstrated a consistent pattern of selling activity in his holdings of Better Therapeutics, Inc. (BETR) over recent months, according to SEC Form 4 filings. Calamari has executed 42 trades, all involving BETR, with no recorded purchases and total sales amounting to $1,932,693.08. Notably, his recent activity includes 10 sell transactions, with significant sales occurring on October 6, 2025, where he sold shares in multiple tranches totaling $718,843.96. These transactions ranged from $14,039.18 to $232,819.25, indicating a substantial reduction in his position.
In addition to the October sales, Calamari has continued to sell shares periodically, with transactions recorded on November 1, 2025 ($114,427.23), December 1, 2025 ($79,050.24), and February 17, 2026 ($262,572.20). His selling activity appears systematic, with smaller sales interspersed throughout the period, such as $41,615.63 on February 1, 2026, and $47,078.10 on January 1, 2026. The absence of any buy transactions suggests a clear bias toward divestment rather than accumulation of BETR shares. While the filings do not disclose the reasons behind these sales, the data underscores a consistent trend of reducing his stake in the company over time.
AI-assisted summary